Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort study
Chhay Lim, Priyadarshini Sinha, Simon J Harrison, Hang Quach, Monica A Slavin, Benjamin W Teh
Mycoses | WILEY | Published : 2020
INTRODUCTION: A multi-centre study to determine the outcomes and risks for invasive fungal disease (IFD) in myeloma (MM) patients treated with second-generation immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies was conducted. METHODS: Clinical and microbiology records were reviewed to capture patient demographics, disease characteristics, treatment, IFD episodes and outcomes. Categorical and continuous variables between patients with IFD and without IFD were compared using chi-square test, Fisher's exact test and Mann-Whitney rank sum test, respectively, with P-value < .05 considered statistically significant. RESULTS: Five out of 148 (3.4%) MM patients were diagnosed w..View full abstract
This study was supported by funding from Merck Sharp and Dohme. BWT is supported by National Health and Medical Research Council Early Career Fellowship and Royal Australasian College of Physicians Robert Maple Brown Fellowship 2019.